Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
about
Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep.Review of mifamurtide in the treatment of patients with osteosarcoma.The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin.Toward a drug development path that targets metastatic progression in osteosarcoma.Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis.Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis.Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investmentStrategies and developments of immunotherapies in osteosarcomaThe Current and Future Therapies for Human Osteosarcoma.Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases.Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.Mifamurtide for the treatment of nonmetastatic osteosarcomaThe immunotherapy of canine osteosarcoma: a historical and systematic review.Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases.
P2860
Q31018689-7417726C-6290-4638-9B81-9754D3D17E91Q33889409-E7BF0232-36CE-4F86-927F-485976740853Q33947618-0BCB2486-D46D-495A-AACB-0DCD98176641Q34044072-59BBB6C8-C2BB-41F2-882C-2EF9E84F853BQ34052760-64CCCBE5-D93B-42FD-889B-EB8A80DA0E70Q34088081-6BF842FE-6069-446B-ABDE-22093C4410E0Q34132358-55736C9D-063F-40F8-945D-25E059858001Q35945493-358AE3BD-A7E5-4A06-AA81-691246B86F17Q35958048-311562F1-F2A7-4504-B123-E0E9940C9500Q36503128-89CB2E75-51CD-41B7-AC07-1C4ABCC05F26Q36514299-7315A056-4843-4D95-8345-1FE6947D2446Q37324303-43CD8532-374D-408E-9D2F-24FF2BD5F008Q37439345-9695B2C4-6C6E-4319-B8AB-96613C17477CQ37827876-949F73B9-48D8-4724-9386-39583913C942Q38451770-D303B493-F118-47EE-9F45-C56CFE5E0FC5Q55323964-225E3DE1-7A4E-40A6-AE80-BEDCAFA0ACCA
P2860
Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
description
1995 nî lūn-bûn
@nan
1995 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Efficacy of liposomal muramyl ...... ment of relapsed osteosarcoma.
@ast
Efficacy of liposomal muramyl ...... ment of relapsed osteosarcoma.
@en
Efficacy of liposomal muramyl tripeptide
@nl
type
label
Efficacy of liposomal muramyl ...... ment of relapsed osteosarcoma.
@ast
Efficacy of liposomal muramyl ...... ment of relapsed osteosarcoma.
@en
Efficacy of liposomal muramyl tripeptide
@nl
prefLabel
Efficacy of liposomal muramyl ...... ment of relapsed osteosarcoma.
@ast
Efficacy of liposomal muramyl ...... ment of relapsed osteosarcoma.
@en
Efficacy of liposomal muramyl tripeptide
@nl
P2093
P1476
Efficacy of liposomal muramyl ...... ment of relapsed osteosarcoma.
@en
P2093
D A Johnston
E S Kleinerman
R S Benjamin
P577
1995-04-01T00:00:00Z